These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 22804100)
21. Penetration of moxifloxacin into liver tissue. Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219 [TBL] [Abstract][Full Text] [Related]
23. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080 [TBL] [Abstract][Full Text] [Related]
24. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335 [TBL] [Abstract][Full Text] [Related]
26. Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Wiesner G; Martin K; Gertler R; Braun SL; Tassani P; Lange R; Gruber M Int J Antimicrob Agents; 2013 May; 41(5):473-6. PubMed ID: 23481660 [TBL] [Abstract][Full Text] [Related]
27. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Holland EJ; Lane SS; Kim T; Raizman M; Dunn S Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration. Abd El-Aty AM; Goudah A; Shah SS; Shin HC; Shimoda M; Shim JH J Vet Pharmacol Ther; 2007 Dec; 30(6):586-91. PubMed ID: 17991229 [No Abstract] [Full Text] [Related]
30. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Pranger AD; van Altena R; Aarnoutse RE; van Soolingen D; Uges DR; Kosterink JG; van der Werf TS; Alffenaar JW Eur Respir J; 2011 Oct; 38(4):888-94. PubMed ID: 21310881 [TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522 [TBL] [Abstract][Full Text] [Related]